New Indication Alert: FDA Approves AbbVie’s Skyrizi® (Risankizumab) for Ulcerative Colitis

On 18 June 2025, AbbVie announced that the FDA approved its Skyrizi® (Risankizumab) for ulcerative colitis, expanding AbbVie’s portfolio across inflammatory bowel disease. 

AbbVie’s Skyrizi® (risankizumab) was approved in November 2023 by the Korean Ministry of Food and Drug Safety (MFDS) to treat adult patients with moderate to severe active Crohn’s disease who have not responded adequately to or cannot tolerate existing therapies.